Cohance Lifesciences

Executive Summary

Cohance Lifesciences is a technology-led contract development and manufacturing organization (CDMO) headquartered in Hyderabad, India. Founded in 2020 and employing over 1,000 people, the company offers end-to-end services for small-molecule active pharmaceutical ingredients (APIs), specialty chemicals, antibody-drug conjugates (ADCs), and nucleic-acid therapeutics. By integrating chemistry, bioconjugation, and GMP-grade manufacturing across multiple sites, Cohance accelerates partner pipelines from discovery through commercial scale. Its focus on high-growth modalities such as ADCs and nucleic acids positions it well in the expanding global CDMO market, particularly as pharmaceutical companies seek reliable and cost-effective outsourcing partners in India. Cohance differentiates itself through its integrated platform and expertise in complex conjugate and nucleic-acid manufacturing, which are areas of increasing demand. The company benefits from India's competitive cost structure and the global trend toward outsourcing non-core drug development and manufacturing. Although private and lacking disclosed financials, its rapid scaling and established infrastructure suggest strong execution. The CDMO sector is poised for steady growth, driven by pipeline expansions and the need for capacity. Cohance is well-positioned to capture market share, though risks include intense competition and regulatory compliance challenges. Its continued investment in new capabilities and strategic partnerships will be key to sustaining momentum.

Upcoming Catalysts (preview)

• Q3 2026Commissioning of new ADC manufacturing facility70% success
• Q4 2026Strategic partnership with a top-20 biopharma for nucleic acid therapeutics60% success
• Q1 2027Receipt of GMP certification for oligonucleotide production line80% success